BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Graham C, Orr C, Bricks CS, Hopman WM, Hammad N, Ramjeesingh R. A retrospective analysis of the role of proton pump inhibitors in colorectal cancer disease survival. Curr Oncol 2016;23:e583-8. [PMID: 28050148 DOI: 10.3747/co.23.3204] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Indini A, Petrelli F, Tomasello G, Rijavec E, Facciorusso A, Grossi F, Ghidini M. Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis. Cancers (Basel). 2020;12. [PMID: 32325628 DOI: 10.3390/cancers12040998] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
2 Murphy N, Moreno V, Hughes DJ, Vodicka L, Vodicka P, Aglago EK, Gunter MJ, Jenab M. Lifestyle and dietary environmental factors in colorectal cancer susceptibility. Mol Aspects Med 2019;69:2-9. [PMID: 31233770 DOI: 10.1016/j.mam.2019.06.005] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 15.7] [Reference Citation Analysis]
3 Meriggi F. Controversial link between proton pump inhibitors and anticancer agents: review of the literature. Tumori 2021;:3008916211025091. [PMID: 34159850 DOI: 10.1177/03008916211025091] [Reference Citation Analysis]
4 Wong GG, Ha V, Chu MP, Dersch-Mills D, Ghosh S, Chambers CR, Sawyer MB. Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer. Clin Colorectal Cancer 2019;18:72-9. [PMID: 30551953 DOI: 10.1016/j.clcc.2018.11.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
5 Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 2021; 27(44): 7716-7733 [PMID: 34908809 DOI: 10.3748/wjg.v27.i44.7716] [Reference Citation Analysis]
6 Matsuoka H, Ando K, Swayze EJ, Unan EC, Mathew J, Hu Q, Tsuda Y, Nakashima Y, Saeki H, Oki E, Bharti AK, Mori M. CTDSP1 inhibitor rabeprazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer. PLoS One 2020;15:e0228002. [PMID: 32764831 DOI: 10.1371/journal.pone.0228002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]